Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The KetMo study is an investigator-initiated, randomized, parallel group, double blinded
trial investigating if ketamine as an adjunct to morphine improves pain treatment in the ED.
Patients in pain (assessed on NRS, 5 or more) will be randomized to low-dose ketamine or
placebo as an adjunct to morphine. Patients with or without prior use of opioids will be
randomized separately.
The primary outcome will be pain reduction, assessed on NRS, after 10 minutes. Secondary
outcomes include pain reduction until 120 minutes after injection of study medicine, need for
rescue opioid, side effects and patient- and provider satisfaction.